However, given the multi-pathophysiological basis of pathology, neurodegeneration and clinical dementia of AD and commonly comorbid pathologies such as cerebrovascular disease and diabetes, it is important to develop a wider set of biomarkers, beyond Ab and tau 8. This evidence concerns the gene MAPT and Alzheimer disease.